CClinicalTrials.gg
Sign In
Status unknownNCT05788874Updated Apr 14, 2023

Study of 18F-FAPI Applied to Gastrointestinal Cancer

An observational study in Gastrointestinal Cancer, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Status unknown. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-14.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Comparison of tumor volume, number, and SUVmax of different primary foci (gastric, duodenal, and colon cancer), lymph node metastases (neck and supraclavicular, mediastinal, abdominal, and pelvic), and distant metastases (brain, lung, liver, bone, pleura, and peritoneum) detected by 18F-FAPI versus 18F-FDG PET/CT imaging.

02

Conditions studied

  • Gastrointestinal Cancer
03

In context

Gastrointestinal Neoplasms

779 studies on the registry are indexed under Gastrointestinal Neoplasms; 231 are open to participants now.

This study's planned enrollment of 50 is below the median of 197 across 176 observational studies indexed under Gastrointestinal Neoplasms.

Browse Gastrointestinal Neoplasms studies →

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 306 studies on the registry; 86 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

  • Patients with high clinical suspicion of gastrointestinal tumor and negative 18F-FDG at first diagnosis
  • Post-treatment patients with high clinical suspicion of recurrence or metastasis and negative 18F-FDG

Inclusion criteria

  • Patients with high clinical suspicion of gastrointestinal tumor and negative 18F-FDG at first diagnosis
  • Post-treatment patients with high clinical suspicion of recurrence or metastasis and negative 18F-FDG

Exclusion criteria

Exclusion Criteria:

  • The diagnosis can be clarified by 18F-FDG PET/CT examination
  • The presence of recurrence or metastasis can be clarified by 18F-FDG PET/CT examination
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • 18F-FDG

    Diagnostic Test: 18F-FAPI and 18F-FDG PET/CT

  • 18F-FAPI

    Diagnostic Test: 18F-FAPI and 18F-FDG PET/CT

Interventions

  • Diagnostic test18F-FAPI and 18F-FDG PET/CT

    18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer

06

What researchers measure

Primary outcomes

  1. SUVmax

    Measurement of the maximum standardized uptake value of the lesion

    Time frame: 1 day (During the inspection)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05788874
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Responsible party
Sponsor
First posted
Mar 29, 2023
Start date
May 2023 (estimated)
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Apr 14, 2023

Study contacts

Yan Li
Contact
29396779@qq.com
0086-15829364429

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Gastrointestinal Neoplasms→

Other studies from this sponsor

First Affiliated Hospital Xi'an Jiaotong University

Start the discussion